Guggenheim raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $21 from $20 and keeps a Buy rating on the shares. The firm adjusted models, forecasts and targets for a number of its Diagnostics and Life Sciences Tools covered companies to reflect recent updates and selected pre-announcements of preliminary results last week.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- Adaptive Biotechnologies: Strong MRD Momentum and Path to 2026 Profitability Support Buy Rating
- Adaptive Biotechnologies Reports Strong Preliminary Q4 2025 Growth
- Adaptive Biotechnologies sees Q4 revenue $72M, consensus $59.38M
- Adaptive Biotechnologies price target raised to $20 from $19 at TD Cowen
- Adaptive Biotechnologies subsidiary completes key Series A financing